PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+10.41%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.49B
AUM Growth
+$2.49B
(+15%)
Cap. Flow
+$216M
Cap. Flow
% of AUM
8.7%
Top 10 Holdings %
Top 10 Hldgs %
34.88%
Holding
90
New
15
Increased
23
Reduced
16
Closed
9
Top Buys
| 1 |
Biogen
BIIB
|
$56.5M |
| 2 |
Stryker
SYK
|
$41.2M |
| 3 |
Icon
ICLR
|
$37.3M |
| 4 |
Alkermes
ALKS
|
$36M |
| 5 |
AbbVie
ABBV
|
$29M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$35.7M |
| 2 |
Avantor
AVTR
|
$28.6M |
| 3 |
uniQure
QURE
|
$23.5M |
| 4 |
Ascendis Pharma
ASND
|
$21.7M |
| 5 |
ICU Medical
ICUI
|
$20.2M |
Sector Composition
| 1 | Healthcare | 98.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Danaher
DHR
$145B
| $42.2M | 1.64% |
175,690
| – | – |
|
27
Tenet Healthcare
THC
$16.4B
| $41.6M | 1.62% |
511,394
+154,453
| +43% | +$12.6M |
|
|
28
Stryker
SYK
$148B
| $41.2M | 1.6% |
+135,022
| New | +$41.2M |
|
29
argenx
ARGX
$43.8B
| $40.8M | 1.58% |
104,732
| – | – |
|
30
Becton Dickinson
BDX
$52.8B
| $40.6M | 1.58% |
153,955
+2,942
| +2% | +$777K |
|
|
31
Alkermes
ALKS
$5.1B
| $36M | 1.4% |
+1,151,384
| New | +$36M |
|
32
Axsome Therapeutics
AXSM
$6.14B
| $35.6M | 1.38% |
495,582
-110,499
| -18% | -$7.94M |
|
33
Dynavax Technologies
DVAX
$1.19B
| $34.9M | 1.36% |
2,704,917
-1,100,453
| -29% | -$14.2M |
|
34
Elevance Health
ELV
$71.8B
| $33.4M | 1.3% |
75,122
+42,539
| +131% | +$18.9M |
|
35
Thermo Fisher Scientific
TMO
$183B
| $32.4M | 1.26% |
62,143
| – | – |
|
36
Acadia Healthcare
ACHC
$2.17B
| $30.4M | 1.18% |
381,302
+70,367
| +23% | +$5.6M |
|
37
BioMarin Pharmaceuticals
BMRN
$11.3B
| $30.4M | 1.18% |
350,298
+190,732
| +120% | +$16.5M |
|
|
KRTX
38
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $30M | 1.16% |
138,209
| – | – |
|
39
Arcus Biosciences
RCUS
$1.21B
| $28.5M | 1.11% |
1,405,056
-154,891
| -10% | -$3.15M |
|
40
Waters Corp
WAT
$17.5B
| $25.2M | 0.98% |
94,624
| – | – |
|
41
Apellis Pharmaceuticals
APLS
$3.55B
| $25M | 0.97% |
274,498
-9,771
| -3% | -$890K |
|
|
BLUE
42
DELISTED
bluebird bio
BLUE
| $24M | 0.93% |
7,285,121
+2,699,339
| +59% | +$8.88M |
|
43
Caribou Biosciences
CRBU
$179M
| $23.7M | 0.92% |
5,570,869
+558,751
| +11% | +$2.37M |
|
44
Sarepta Therapeutics
SRPT
$1.95B
| $19M | 0.74% |
+165,765
| New | +$19M |
|
|
RETA
45
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $14.8M | 0.57% |
+145,147
| New | +$14.8M |
|
46
Boston Scientific
BSX
$159B
| $14.5M | 0.56% |
+268,397
| New | +$14.5M |
|
47
Generation Bio
GBIO
$41.2M
| $14.3M | 0.55% |
2,597,436
-50,861
| -2% | -$280K |
|
48
Day One Biopharmaceuticals
DAWN
$772M
| $13.7M | 0.53% |
+1,147,140
| New | +$13.7M |
|
49
Erasca
ERAS
$403M
| $13.2M | 0.51% |
4,797,460
| – | – |
|
|
PNT
50
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $11.8M | 0.46% |
1,299,491
-1,905,299
| -59% | -$17.3M |
|